本文關(guān)鍵詞：基于“毒損腸絡(luò)”的加味五得湯治療UC（活動(dòng)期）的臨床研究　出處：《山東中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： “毒損腸絡(luò)” 潰瘍性結(jié)腸炎 活動(dòng)期 加味五得湯 芩藤愈瘍湯

【摘要】：目的:根據(jù)“毒損腸絡(luò)”的假說(shuō),觀察加味五得湯口服聯(lián)合芩藤愈瘍湯保留灌腸治療活動(dòng)期潰瘍性結(jié)腸炎(ulcerative colitis,UC)(輕中度,大腸濕熱型)的臨床療效,以期揭示中醫(yī)藥的治療優(yōu)勢(shì),為臨床治療UC提供新思路。方法:選擇符合納入標(biāo)準(zhǔn)的UC活動(dòng)期患者60例,隨機(jī)分為兩組:對(duì)照組30例給予美沙拉嗪(艾迪莎),1.0g,po,qid;試驗(yàn)組30例,給予加味五得湯口服,日1劑,聯(lián)合芩藤愈瘍湯保留灌腸,每晚1次。2周為一個(gè)療程,每?jī)蓚�(gè)療程間隔2天,兩組共治療3個(gè)療程。結(jié)束后記錄兩組治療前后單項(xiàng)癥狀積分、總積分、中醫(yī)證候、綜合療效、結(jié)腸鏡下黏膜病變、疾病活動(dòng)指數(shù),運(yùn)用SPSS17.0統(tǒng)計(jì)軟件對(duì)所得資料進(jìn)行分析比較。結(jié)果:在腹瀉、膿血便、腹脹、里急后重、發(fā)熱及總癥狀積分方面試驗(yàn)組優(yōu)于對(duì)照組,兩組有統(tǒng)計(jì)學(xué)差異(p0.05),而在改善肛門(mén)灼熱、溲赤癥狀上兩組無(wú)統(tǒng)計(jì)學(xué)差異(p0.05);中醫(yī)證候療效、綜合療效積分的改變上兩組均較前明顯改善,且試驗(yàn)組優(yōu)于對(duì)照組,兩組有統(tǒng)計(jì)學(xué)差異(p0.05);在Mayo評(píng)分方面兩組均較療前明顯改善,且試驗(yàn)組優(yōu)于對(duì)照組,兩組有統(tǒng)計(jì)學(xué)差異(p0.05);治療后鏡下粘膜病變療效比較中,試驗(yàn)組仍好于對(duì)照組,兩組有統(tǒng)計(jì)學(xué)差異(p0.05);兩組在受試期間均未出現(xiàn)明顯不良反應(yīng)。結(jié)論:基于“毒損腸絡(luò)”假說(shuō),臨床上給予活動(dòng)期UC(輕中度,大腸濕熱型)患者加味五得湯口服聯(lián)合芩藤愈瘍湯保留灌腸,在改善患者諸多不適的主觀感受及結(jié)腸鏡下粘膜病變改善等的客觀指標(biāo)方面都具有其獨(dú)特的優(yōu)勢(shì)。提示中醫(yī)藥治療UC有明顯優(yōu)勢(shì),并且臨床應(yīng)用比較安全可靠。
[Abstract]:Objective: according to the hypothesis of "toxic damage to the collaterals", the observation of Jiawei Wude decoction combined with Qinteng Yuyang decoction retention enema treatment of active ulcerative colitis ulcerative colitis. The clinical effect of UCU (mild to moderate, large intestine damp-heat type) in order to reveal the advantages of traditional Chinese medicine (TCM) and provide a new idea for clinical treatment of UC. Methods: 60 patients with UC active stage who met the inclusion criteria were selected. They were randomly divided into two groups: the control group (n = 30) was treated with mezalazine (1. 0 g / kg) and the control group (n = 30); In the experimental group, 30 cases were treated with Jiawei Wudai decoction orally, once a day, combined with Qinteng Yuyang decoction to retain enema, once a night for 2 weeks as a course of treatment, every two courses of treatment interval 2 days. After the two groups were treated for 3 courses of treatment, the single symptom score, total score, TCM syndromes, comprehensive curative effect, mucosal lesion under colonoscopy and disease activity index were recorded before and after treatment. SPSS17.0 statistical software was used to analyze and compare the data. Results: the experimental group was superior to the control group in the aspects of diarrhea, purulent stool, abdominal distension, acute and severe, fever and total symptom score. There was a significant difference between the two groups (P 0.05), but there was no significant difference in the symptoms of Deutzia. The changes of syndromes and integrals of TCM syndrome in the two groups were obviously improved compared with the former, and the experimental group was better than the control group, there was statistical difference between the two groups (P 0.05). The Mayo scores of the two groups were significantly improved compared with those before treatment, and the experimental group was superior to the control group, and the two groups had statistical difference (P 0.05). Compared with the control group, the treatment group was still better than the control group, there was a statistical difference between the two groups (P 0.05). Conclusion: based on the hypothesis of "toxic damage to intestinal collaterals", active UC (mild to moderate) was given clinically. Large intestine damp-heat type) patients with modified Wude decoction oral combined with Qinteng Yuyang decoction retention enema. It has its unique advantage in improving the subjective feeling of many discomfort patients and the objective index of improving mucosal lesions under colonoscopy. It suggests that Chinese medicine has obvious advantages in the treatment of UC. And clinical application is relatively safe and reliable.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R259

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉成明;王麗;寧俞媛;;三七粉對(duì)小鼠免疫調(diào)節(jié)功能的影響[J];亞太傳統(tǒng)醫(yī)藥;2015年23期

2 呂生輝;馮德魁;;化毒愈瘍方保留灌腸治療輕、中度潰瘍性結(jié)腸炎43例[J];中國(guó)實(shí)驗(yàn)方劑學(xué)雜志;2015年02期

3 張向陽(yáng);魏紅;鄭海萍;田河林;趙如同;;地榆炭的研究進(jìn)展[J];環(huán)球中醫(yī)藥;2014年02期

4 李敏;;山藥活性成分提取技術(shù)及藥理功能的研究進(jìn)展[J];南方農(nóng)業(yè)學(xué)報(bào);2013年07期

5 莫好紅;;美沙拉嗪腸溶片與水楊酸柳氮磺胺嘧啶腸溶片治療潰瘍性結(jié)腸炎的療效觀察[J];醫(yī)學(xué)理論與實(shí)踐;2013年13期

6 李曦;張麗宏;王曉曉;楊雯;金玉青;呂光華;;當(dāng)歸化學(xué)成分及藥理作用研究進(jìn)展[J];中藥材;2013年06期

7 王新月;閆昕;;潰瘍性結(jié)腸炎的發(fā)病特點(diǎn)與“毒損腸絡(luò)”病機(jī)學(xué)說(shuō)[J];中國(guó)中西醫(yī)結(jié)合雜志;2013年03期

8 韓亮;劉昌輝;;敗醬草對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸TNF-α、IL-1β及IL-10表達(dá)的干預(yù)作用[J];今日藥學(xué);2013年02期

9 楊蕾;陳麗霞;俞騰飛;;黃連吳茱萸現(xiàn)代藥學(xué)研究進(jìn)展及配伍變化[J];內(nèi)蒙古中醫(yī)藥;2012年23期

10 林燕;李建;;基于“毒損腸絡(luò)”理論的潰瘍性結(jié)腸炎復(fù)發(fā)病機(jī)探微[J];中國(guó)臨床醫(yī)生;2012年11期

相關(guān)會(huì)議論文 前1條

1 劉慧榮;趙天平;吳煥淦;;從腸絡(luò)角度探討炎癥性腸病病理機(jī)制[A];2011中國(guó)針灸學(xué)會(huì)年會(huì)論文集（摘要）[C];2011年

相關(guān)碩士學(xué)位論文 前2條

1 黃勝林;基于伏毒理論探討MMP-1、TIMP-1在潰瘍性結(jié)腸炎中的作用[D];廣州中醫(yī)藥大學(xué);2014年

2 馬亦e，

本文編號(hào)：1367381